NHS Consultant Chest Physician; Honorary Professor of Respiratory Medicine; Chief Clinical Officer INFEX Therapeutics: AMR & sustainable antimicrobial pipeline
United Kingdom
Joined July 2019
- Tweets108
- Following772
- Followers291
- Likes1.3K
I am biased but this is a fabulous interstitial lung disease course. Best to get registered quickly as it is usually oversubscribed
Join as at the Manchester Interstitial Lung Diseases (MILD) 2026 on 26th/27th March @ConalHayton @LeonardColm @CristinaAvram8 @JBlaikley
Booking link below!
Be wary of using @FedEx for deliveries from USA to UK. My new stethoscope arrived in UK one week ago & I still have not received it. FedEx live chat & phone numbers do not allow human conversation! Appalling service
Beware flying with @FlyLoganair as my Wife experiencing terrible customer service Manchester to Aberdeen . Flew yesterday to Aberdeen, no baggage put on plane, told it would be on following flight, 2 flights later bag still in Manchester. Loganair unhelpful as is handling agent
Very excited to work with Asian ADVANCE-ID network to plan clinical trials of our novel metallo-beta-lactamase (MBL) inhibitor, MET-X. Antimicrobials targeting MBL mechanism of Gram negative bacterial resistance to antibiotics is key gap in pipeline. @davidantibiotic @INFEX_TX
Infex agrees collaboration with Asian clinical trials network, ADVANCE-ID
Memorandum of Understanding signed to investigate hospital-acquired drug-resistant infections in Asia:
infextx.com/infex-agrees-col…
Excited to share our licensing deal in India for clinical development of MET-X our novel metallobetalactamase (MBL) inhibitor. MBL mechanism of resistance is an enormous problem in India & SE Asia & a rising problem EU & USA. MBL mechanism is a key pipeline priority for WHO
Infex signs exclusive license agreement with Venus Remedies Ltd to advance MET-X through clinical development and commercialisation in India:
infextx.com/infex-signs-excl…
Novel pathways to combat antimicrobial resistance sorely needed. Its super that with this PACE funding INFEX & the team at Justus-Liebig-University Giessen can now advance this exciting BamA inhibitor project towards clinical trial readiness
Infex and Justus-Liebig-University Giessen awarded £1 million grant from PACE:
infextx.com/infex-and-justus…
colm leonard retweeted
📊 New data from @UKHSA: Antibiotic-resistant infections in 2023 exceeded pre-pandemic levels
An alarming 66,730 serious cases were reported - compared to 62,314 in 2019.
👉gov.uk/government/news/antib…
This is scary, warzone superbugs come to visit! Funders, regulators, HTA entities need to facilitate antibiotic pipeline to have necessary armoury to fight this threat. Antimicrobial resistance is not a silent threat. Antimicrobial BioTech needs support harvardpublichealth.org/glob…
Looks like a super programme, thanks for sharing Chris.
Looking forward to chairing the Antimicrobial Chemotherapy Conference next week (6-7th Feb). It's a free virtual meeting organised jointly by GARDP and BSAC with an exciting programme covering the whole antimicrobial development pathway. Register Here: acc-conference.com/2023-conf…
colm leonard retweeted
📣 @INFEX_TX is on a mission to combat new COVID strains and is searching for a global pharma partner.
Read more about their new treatment for COVID variants below ⬇️ bit.ly/45jwo5H
colm leonard retweeted
Infex Therapeutics Clinical candidate nominated for COV-X programme
📈COV-X outperforms Pfizer's approved antiviral
🌟Unique target: potential for broad efficacy against new coronaviruses
🦠Emerging resistance to existing Mpro inhibitors
infextx.com/clinical-candida…
#COVID19
Alarming antibiotic resistance discovered in war-torn Ukraine- this is truly frightening, the not so silent pandemic of AMR, 10% resistance to Colistin! medicalxpress.com/news/2023-…
colm leonard retweeted
We are recruiting healthy volunteers for a trial with @INFEX_TX. The full details are below 👇
Contact us to find out how you can #GetInvolvedinResearch
@LivHospitalsRI @LivHospitals
colm leonard retweeted
Questions about the UK Subscription Program for Antibacterials? See our Open Access article out today. Kudos to Team UK for leading the world. link.springer.com/article/10…
w @JohnRex_NewAbx
Can the UK 'Netflix' Payment Model Boost the Antibacterial Pipeline? - PubMed pubmed.ncbi.nlm.nih.gov/3664…
colm leonard retweeted
'Can the UK's Netflix payment model boost the antibacterial pipeline?'
Great insights on the how the project was devised & developed - sharing lessons learned - from @LeonardColm and team:
pubmed.ncbi.nlm.nih.gov/3664…
#pullincentives #antibioticresistance #innovation
Delighted to share our publication on the NICE & NHS England project to deliver novel value assessment & reimbursement for new antimicrobial @NICEComms @NHSEngland trebuchet.public.springernat…
Delighted to share our publication on the NICE & NHS England project to deliver novel value assessment & reimbursement for new antimicrobial @NICEComms @NHSEngland trebuchet.public.springernat…
colm leonard retweeted
🚨 Northern Ireland and Manchester Interstitial Lung Disease Course which will be held on 2nd -3rd March 2023 🚨 #Manchester 🇬🇧
🫁 #ILD #CTD_ILD #PFILD #PostCOVID_ILD #AEILD #MDT 🫁 We look forward to seeing you there!
You can see the programme and the link to register below 👇
Dear #ILD Colleague,
I am delighted to invite you to the Northern Ireland and Manchester Interstitial Lung Diseases Meeting which will be held on 2-3 March 2023.
To register your place please visit the following link to Eventbrite:
eventbrite.co.uk/e/northern-…
Category 13 CPD credits
